17-61744432-CTT-C

Variant summary

Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong

The NM_032043.3(BRIP1):​c.2255_2256del​(p.Lys752ArgfsTer12) variant causes a frameshift, splice region change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000434 in 1,613,142 control chromosomes in the GnomAD database, with no homozygous occurrence. 1/1 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Pathogenic (β˜…β˜…). Variant results in nonsense mediated mRNA decay.

Frequency

Genomes: 𝑓 0.000033 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000044 ( 0 hom. )

Consequence

BRIP1
NM_032043.3 frameshift, splice_region

Scores

Not classified

Clinical Significance

Pathogenic criteria provided, multiple submitters, no conflicts P:11

Conservation

PhyloP100: 3.44
Variant links:
Genes affected
BRIP1 (HGNC:20473): (BRCA1 interacting helicase 1) The protein encoded by this gene is a member of the RecQ DEAH helicase family and interacts with the BRCT repeats of breast cancer, type 1 (BRCA1). The bound complex is important in the normal double-strand break repair function of breast cancer, type 1 (BRCA1). This gene may be a target of germline cancer-inducing mutations. [provided by RefSeq, Jul 2008]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Pathogenic. Variant got 16 ACMG points.

PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PP5
Variant 17-61744432-CTT-C is Pathogenic according to our data. Variant chr17-61744432-CTT-C is described in ClinVar as [Pathogenic]. Clinvar id is 182372.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr17-61744432-CTT-C is described in Lovd as [Pathogenic].

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE Protein UniProt
BRIP1NM_032043.3 linkuse as main transcriptc.2255_2256del p.Lys752ArgfsTer12 frameshift_variant, splice_region_variant 15/20 ENST00000259008.7 NP_114432.2

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Protein Appris UniProt
BRIP1ENST00000259008.7 linkuse as main transcriptc.2255_2256del p.Lys752ArgfsTer12 frameshift_variant, splice_region_variant 15/201 NM_032043.3 ENSP00000259008 P2Q9BX63-1

Frequencies

GnomAD3 genomes
AF:
0.0000329
AC:
5
AN:
152000
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000735
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.0000119
AC:
3
AN:
251052
Hom.:
0
AF XY:
0.0000221
AC XY:
3
AN XY:
135652
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.0000264
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.0000445
AC:
65
AN:
1461142
Hom.:
0
AF XY:
0.0000358
AC XY:
26
AN XY:
726826
show subpopulations
Gnomad4 AFR exome
AF:
0.00
Gnomad4 AMR exome
AF:
0.00
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.0000558
Gnomad4 OTH exome
AF:
0.0000497
GnomAD4 genome
AF:
0.0000329
AC:
5
AN:
152000
Hom.:
0
Cov.:
32
AF XY:
0.0000135
AC XY:
1
AN XY:
74202
show subpopulations
Gnomad4 AFR
AF:
0.00
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.0000735
Gnomad4 OTH
AF:
0.00
Bravo
AF:
0.0000302
EpiCase
AF:
0.00
EpiControl
AF:
0.0000593

ClinVar

Significance: Pathogenic
Submissions summary: Pathogenic:11
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Hereditary cancer-predisposing syndrome Pathogenic:3
Pathogenic, criteria provided, single submitterclinical testingColor Diagnostics, LLC DBA Color HealthJun 02, 2022This variant deletes 2 nucleotides in exon 15 of the BRIP1 gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has been reported in individuals with breast cancer (PMID: 17033622, 26681682, 26976419) and ovarian cancer (PMID: 26315354, 26681312, 29368626), as well as in an individual affected with Fanconi anemia (PMID: 16116423). This variant has been identified in 3/251052 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of BRIP1 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. -
Pathogenic, criteria provided, single submitterclinical testingAmbry GeneticsOct 28, 2021The c.2255_2256delAA pathogenic mutation, located in coding exon 14 of the BRIP1 gene, results from a deletion of two nucleotides at nucleotide positions 2255 to 2256, causing a translational frameshift with a predicted alternate stop codon (p.K752Rfs*12). This mutation was seen in conjunction with a second BRIP1 alteration in a patient with Fanconi anemia complementation group J (Levitus M et al. Nat. Genet. 2005 Sep;37:934-5). It has also been seen in patients with breast and/or ovarian cancer (Ramus SJ et al. J Natl Cancer Inst. 2015 Nov;107; Susswein LR et al. Genet. Med. 2016 Aug;18:823-32; Tung N et al. J Clin Oncol. 2016 May;34:1460-8; Carter NJ et al. Gynecol Oncol. 2018 12;151:481-488; Weber-Lasalle N et al. Breast Cancer Res. 2018 Jan;20(1):7). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
Pathogenic, criteria provided, single submittercurationSema4, Sema4Sep 02, 2021- -
not provided Pathogenic:2
Pathogenic, criteria provided, single submitterclinical testingQuest Diagnostics Nichols Institute San Juan CapistranoMar 27, 2019This variant alters the translational reading frame of the BRIP1 mRNA and causes the premature termination of BRIP1 protein synthesis. This variant has been reported in individuals with breast cancer, ovarian cancer, and Fanconi Anemia complementation group J (FA-J) in the published literature (PMID: 26976419 (2016), 26681312 (2018), 26681312 (2015), 16116423 (2005)). Based on the available information, this variant is classified as pathogenic. -
Pathogenic, criteria provided, single submitterclinical testingGeneDxApr 04, 2024Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Observed in individuals with a personal or family history consistent with pathogenic variants in this gene (PMID: 17033622, 26315354, 26976419, 29368626, 32359370); Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 28152038, 26681312, 19763819, 26315354, 17033622, 26976419, 29308099, 26681682, 29368626, 20346647, 30322717, 16116423, 32359370, 26689913, 29625052, 29922827, 28888541, 34326862, 34887416, 34308104, 35626031, 36451132) -
Familial cancer of breast Pathogenic:2
Pathogenic, criteria provided, single submitterclinical testingMyriad Genetics, Inc.Feb 28, 2023This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. -
Pathogenic, criteria provided, single submitterclinical testingBaylor GeneticsMar 24, 2024- -
Familial cancer of breast;C1836860:Fanconi anemia complementation group J Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpJan 03, 2024This sequence change creates a premature translational stop signal (p.Lys752Argfs*12) in the BRIP1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRIP1 are known to be pathogenic (PMID: 16116423, 17033622, 21964575). This variant is present in population databases (rs730881649, gnomAD 0.002%). This premature translational stop signal has been observed in individual(s) with ovarian cancer or breast cancer and Fanconi anemia (PMID: 16116423, 26315354, 26681312, 26681682, 26976419). This variant is also known as c.2255_2256delTT. ClinVar contains an entry for this variant (Variation ID: 182372). For these reasons, this variant has been classified as Pathogenic. -
Ovarian neoplasm;C1836860:Fanconi anemia complementation group J Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingCounsylDec 18, 2017- -
Fanconi anemia complementation group J Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingRevvity Omics, RevvityMar 08, 2019- -
Hereditary breast ovarian cancer syndrome Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingWomen's Health and Genetics/Laboratory Corporation of America, LabCorpApr 18, 2016Variant summary: The variant of interest causes a frameshift mutation resulting in a premature termination codon, a known mechanism for disease, as these types of variants are predicted to cause transcript degradation through nonsense mediated decay or produce a truncated protein. The variant of interest was observed in the large, broad control population, ExAC, with an allele frequency of 2/121342 (1/60679), which does not exceed the predicted maximum expected allele frequency for a pathogenic BRIP1 variant of 1/16000. In addition, this observation needs to be cautiously considered due to the cohort including individuals that could harbor a BRIP1 phenotype. The variant of interest has been reported in affected individuals with varying phenotypes BrC, OvC and FANCJ, including the variant of interest segregating with disease (BrC) within one family (Seal_2006). In addition, multiple reputable clinical laboratories cite the variant with a classification of "pathogenic." Therefore, taking all available lines of evidence into consideration, the variant of interest is classified as Pathogenic. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.15
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs730881649; hg19: chr17-59821793; API